Year-end report 2002 Perbio Science AB

Year-end report Perbio Science AB 2002 Good growth and high profitability despite weaker USD · Net sales up 15 percent to SEK 2,175 (1,899) million · Operating profit before amortization of goodwill up 16 percent to SEK 402 (348) million · Income after financial items increased by 15 percent to SEK 367 (318) million · Earnings per share after full dilution up 19 percent to SEK 6.20 (5.20) · Investment in research and development stepped up · Dollar 6 percent weaker than 2001 and 14 percent weaker in Q4 compared to last year · Proposed dividend of SEK 1.50 per share Bioresearch Division · Continued rapid development of new products · Sharper focus on products for protein studies Cell Culture Division · Increased access to serum raw material through acquisition in Australia and start-up in Canada · New facility doubles production capacity for cell culture media and sterile liquids · Focus on serum-free/protein-free cell culture media and innovations in BPC technology Medical Device Division · Focus on products for voice rehabilitation · FreeHands and TrachPhone licensed for sale in the USA · Operation of Therabite Corporation acquired ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/02/11/20030211BIT00330/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/02/11/20030211BIT00330/wkr0002.pdf The full report